Aporte a la rutina de la trinchera asistencial donde los conocimientos se funden con las demandas de los pacientes, sus necesidades y las esperanzas de permanecer en la gracia de la SALUD.
jueves, 31 de agosto de 2023
Emotional dry cleaning: A writer helps doctors share their stories — and their pain Isabella Cueto By Isabella Cueto
Emotional dry cleaning: A writer helps doctors share their stories — and their pain
Isabella Cueto
By Isabella Cueto
https://www.statnews.com/2023/08/30/laurel-braitman-memoir-health-care-workers-writing-workshops/?utm_campaign=morning_rounds&utm_medium=email&_hsmi=272277540&_hsenc=p2ANqtz-8uf9xC3WAsM2vWm7CsajorBz1i6ErL_fQxZ8a2d0jjvQOe2sGfAwDRktIgzWMC8jr31gwmTOYus7wD8RW123HduT2s4A&utm_content=272277538&utm_source=hs_email
NIMH's 75th Anniversary Symposium–In-Person Registration Closing Soon
NIMH's 75th Anniversary Symposium–In-Person Registration Closing Soon
In September, the National Institute of Mental Health (NIMH) is launching its yearlong 75th anniversary celebration with "The Evolution of Mental Health Research" symposium, highlighting key advances in mental health research.
Event date: September 13, 2023
Time: 8:30 a.m.–5:30 p.m. ET
Location: Natcher Conference Center on the NIH campus in Bethesda, MD.
This symposium is free, and registration is required. In-person registration will close on September 5.
https://www.nimh.nih.gov/news/events/the-evolution-of-mental-health-research
AMD Days 2023 APHL, 2023
AMD Days 2023
APHL, 2023
From the website: "CDC OAMD and APHL have co-sponsored AMD day, AMD 2-day, Virtual AMD-days, and now AMD days since 2016. This symposium began as an opportunity for OAMD funded CDC projects to be shared and presented. It has evolved to be an opportunity for state and local public health laboratories, CDC laboratories to present their work, network, and hear from leaders in the field. We are excited to bring back AMD-days! This event will be held September 12-14, 2023 at the CDC Roybal Campus in Atlanta, GA."
https://www.aphl.org/programs/infectious_disease/Pages/AMD-Days.aspx
miércoles, 30 de agosto de 2023
The Lancet Series on racism, xenophobia, discrimination, and health
Advancing equity, diversity, and inclusion (EDI) is a commitment to health for all. The Lancet Group believes science can be an instrument for positive social change, and that journals have an important part to play in challenging systems that do not benefit everyone everywhere.
https://www.thelancet.com/equity-diversity-inclusion?dgcid=hubspot_update_feature_updatealerts_laneur&utm_campaign=update-laneur&utm_medium=email&_hsmi=272193224&_hsenc=p2ANqtz--Z4KSBmoIp1QQMY7pk3CtF3YDc8rPoFFkMc2t_nZBmSfkF8GgUUEk2kVlGFG7djk54lENwNLNRJT-EDOqz_IVpkvvNSA&utm_content=272134703&utm_source=hs_email
martes, 29 de agosto de 2023
Public Comment on Draft Recommendation Statement and Draft Evidence Review: Primary Care Interventions to Prevent Child Maltreatment
https://www.uspreventiveservicestaskforce.org/uspstf/public-comments-and-nominations/opportunity-for-public-comment
The U.S. Preventive Services Task Force seeks comments on a draft recommendation statement and draft evidence review on primary care interventions to prevent child maltreatment. The Task Force is calling for more research on how to prevent child maltreatment before it occurs in children and adolescents who do not show signs or symptoms of abuse and neglect. The draft recommendation statement and draft evidence review are available for review and public comment from August 29, 2023 to September 25, 2023 here.
lunes, 28 de agosto de 2023
FDA approves multiple generics of ADHD and BED treatment (lisdexamfetamine dimesylate)
FDA has approved several first generics of Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets for attention-deficit/hyperactivity disorder (ADHD) in patients six years and older and moderate to severe binge-eating disorder (BED) in adults. See Vyvanse’s prescribing information for details on dosing.
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-multiple-generics-adhd-and-bed-treatment?utm_medium=email&utm_source=govdelivery
domingo, 27 de agosto de 2023
sábado, 26 de agosto de 2023
ONE-TWO PUNCH TO DETECT AND WIPE OUT LUNG CANCER
One-Two Punch to Detect and Wipe Out Lung Cancer
By Ivanhoe Broadcast News on August 16, 2023
https://www.ivanhoe.com/medical-breakthroughs/one-two-punch-to-detect-and-wipe-out-lung-cancer/
BATTLING OBESITY IN TEENS: GROUNDBREAKING GUIDELINES FOR CHILDREN
Battling Obesity in Teens: Groundbreaking Guidelines for Children
By Ivanhoe Broadcast News on August 22, 2023
https://www.ivanhoe.com/medical-breakthroughs/battling-obesity-in-teens-groundbreaking-guidelines-for-children/
TOO MUCH EXERCISE: CAN IT HURT YOUR HEART?
Too Much Exercise: Can it Hurt Your Heart?
By Ivanhoe Broadcast News on August 24, 2023
https://www.ivanhoe.com/medical-breakthroughs/too-much-exercise-can-it-hurt-your-heart/
TEENS AND SOCIAL MEDIA: NEW GUIDELINES FOR PARENTS
Teens and Social Media: New Guidelines for Parents
By Ivanhoe Broadcast News on September 3, 2023
https://www.ivanhoe.com/?p=31174&preview=1&_ppp=ddfe27b033
MORE THAN MEDICINE: BEDSIDE MANNERS MATTER
More Than Medicine: Bedside Manners Matter
By Ivanhoe Broadcast News on September 2, 2023
https://www.ivanhoe.com/?p=31171&preview=1&_ppp=66bdd57eb6
ANTIBIOTIC ALERT: REDUCING DRUG OVERUSE IN KIDS!
Antibiotic Alert: Reducing Drug Overuse in Kids
By Ivanhoe Broadcast News on September 2, 2023
https://www.ivanhoe.com/?p=31168&preview=1&_ppp=5967e46f75
PEANUT PATCH: FIGHTING CHILDHOOD ALLERGIES
Peanut Patch: Fighting Childhood Allergies
By Ivanhoe Broadcast News on August 28, 2023
https://www.ivanhoe.com/?p=31130&preview=1&_ppp=72463ccf86
9/11 FIRST RESPONDERS ARE STILL SAVING LIVES
9/11 First Responders Are Still Saving Lives
By Ivanhoe Broadcast News on August 29, 2023
https://www.ivanhoe.com/?p=31137&preview=1&_ppp=cc6784d966
BREAKING BARRIERS: BARIATRIC SURGERY TO PREVENT CANCER
Bariatric Surgery to Prevent Cancer
By Ivanhoe Broadcast News on August 30, 2023
https://www.ivanhoe.com/?p=31144&preview=1&_ppp=6fe245bc7f
ON THE MOVE: PORTABLE MRI FOR CHILDREN
Portable MRI for Children
By Ivanhoe Broadcast News on August 31, 2023
https://www.ivanhoe.com/?p=31151&preview=1&_ppp=59fc7205f2
NURSING 911: HEALTHCARE STAFFING CRISIS
Nursing 911: Healthcare Staffing Crisis
By Ivanhoe Broadcast News on September 1, 2023
https://www.ivanhoe.com/?p=31165&preview=1&_ppp=942d3b7cfc
The top 10 research priorities for pancreatitis: findings from a James Lind Alliance priority setting partnership
The top 10 research priorities for pancreatitis: findings from a James Lind Alliance priority setting partnership
Sep 2023
Volume 8Number 9p771-860, e7
https://www.thelancet.com/journals/langas/issue/current
Unsilencing liver disease The Lancet Gastroenterology & Hepatology
Unsilencing liver disease
The Lancet Gastroenterology & Hepatology
Sep 2023
Volume 8Number 9p771-860, e7
https://www.thelancet.com/journals/langas/issue/current
viernes, 25 de agosto de 2023
Diagnosis and Treatment of Tethered Spinal Cord
https://effectivehealthcare.ahrq.gov/products/tethered-spinal-cord/protocol
This review will summarize the evidence regarding diagnosis, prophylactic treatment, symptomatic treatment, and repeat surgery of tethered spinal cord. With funding from PCORI, AHRQ commissioned this work to synthesize the findings on the diagnosis and treatment of tethered spinal cord. The systematic review will support the Congress for Neurological Surgeons clinical practice guidelines.
Treatment of Stage I-III Squamous Cell Anal Cancer
Treatment of Stage I-III Squamous Cell Anal Cancer: This is an new protocol for a systematic review that will summarize the state of the evidence on treatment of stage I-III squamous cell carcinoma of the anal canal and anal margin.
This systematic review will assess the effectiveness and harms of treatment for stages I-III squamous cell anal cancer. This review, funded by the Patient-Centered Outcomes Research Institute, will be used by the American Society of Clinical Oncology and the American Society of Radiation Oncology to update clinical practice guidelines.
Diagnosis and Management of Obsessive Compulsive Disorders in Children
Diagnosis and Management of Obsessive Compulsive Disorders in Children: The systematic review will summarize the findings from 1. Studies related to the accuracy of assessment tools compared to reference standard methods to identify OCD in symptomatic youth and 2. Studies of psychological and/or pharmacological treatments of OCD.
This comparative effectiveness review will inform a planned update of the 2012 American Academy of Child and Adolescent Psychiatry (AACAP) Practice Parameter. AACAP nominated this topic to the Patient-Centered Outcomes Research Institute, which contracted with the Agency for Healthcare Research and Quality to conduct the review. Specifically, the systematic review will summarize the findings from 1. Studies related to the accuracy of assessment tools compared to reference standard methods to identify OCD in symptomatic youth and 2. Studies of psychological and/or pharmacological treatments of OCD. The intended audience includes guideline developers, child psychiatrists and psychologists, pediatricians, family physicians, advanced practice providers, parents, and patients.
jueves, 24 de agosto de 2023
The Start-to-Finish of Orphan Drugs From regulation & policy to global pricing to gene therapies
https://www.terrapinn.com/conference/world-orphan-drug-congress/index.stm
30 October 2023 | Pre-Congress Workshops (InterContinental Barcelona - next to Fira de Barcelona)
31 October - 2 November 2023 | Main Congress Days (Fira de Barcelona Montjuic)
Training for patient representatives and advocates on leadership and communication skills 26 October 2023 - 09:00 Gdańsk, Poland
Training for patient representatives and advocates on leadership and communication skills
EJP RD - European Joint Programme on Rare Diseases - Training for patient representatives and advocates on leadership and communication skills
26 October 2023 - 09:00 Gdańsk, Poland
https://www.ejprarediseases.org/event/training-for-patient-representatives-and-advocates-on-leadership-and-communication-skills-2/
Creating Awareness Connecting Families, Funding Research, Maintaining Hope.: Lafora disease: The stories of Robin & Angelina
The journeys of Robin and Angelina, two young individuals living with Lafora Disease, may be separated by thousands of miles, but they intertwine through shared experiences. Lafora disease, a terminal neurodegenerative condition affecting children, currently lacks a cure. EURORDIS sheds a light on Robin's and Angelina's stories and the brilliant work of the Chelsea’s Hope Lafora Children Research Fund.
Would you like to share your story with us about life with a rare disease to support our Community article series? Contact Rhiannon Walls, our Communications Junior Manager, at rhiannon.walls@eurordis.org.
https://chelseashope.org/
SATB2-Associated Syndrome Awareness Day
https://www.satb2europe.org/
Yesterday, on 22 August, our member organisation SATB2 Europe marked SATB2-Associated Syndrome Awareness Day. SATB2-Associated Syndrome (SAS), also known as Glass Syndrome or 2q33.1 Microdeletion Syndrome, is a rare genetic neurodevelopmental disorder caused by alterations of the SATB2 gene on the second chromosome. This syndrome significantly affects many organ systems and thus areas of development, primarily brain, palate, teeth and bones. To learn more about the experiences of those impacted by SAS, listen this discussion with Erika Stariha, the Founding President of SATB2 Europe and the mother of a boy with the condition.
Is your organisation also aware of any upcoming awareness events that you would like to see promoted in the Community section of our monthly newsletter? If yes, contact our Communications Manager, Julien Poulain, at julien.poulain@eurordis.org.
How to START? Four pillars to optimally begin your orphan drug development
https://link.springer.com/article/10.1186/s13023-023-02845-9
Virginie Hivert, our Therapeutic Development Director, was a co-author in a position paper published this month by the Orphanet Journal of Rare Diseases. The position paper, 'How to START? Four pillars to optimally begin your orphan drug development' details best practices for initiating the process of developing medicines to treat rare conditions. The paper proposes a 'START' checklist relating to key considerations when starting an orphan drug development: STakeholder mapping, Available information on the disease, Resources, and Target patient value profile.
Living with Uncertainty & Impact of Trauma Mental Wellbeing Webinar August 2023 - 6 Sep 2023
https://www.eurordis.org/living-with-uncertainty-impact-of-trauma-mental-wellbeing-webinar/
People affected by a rare and undiagnosed condition live with an accumulative impact on their mental wellbeing. Specifically at an individual level, people living with a rare disease (PLWRD) can have an associated mental health co-morbidity, and at a population level, the community live with the increased psychological impact associated with the rare disease journey across all stages of life. Furthermore, the rare disease community has increased exposure to social inequality and discrimination, which are risk factors affecting poor mental wellbeing. The rare disease community has identified the need to look beyond the physiological symptoms of a rare condition, and recognise the importance of psychological support as a fully integrated part of the coordination of care. Without support, there will continue to be a detrimental impact on the mental health of those affected by rare conditions, hindering them from effective participation in society.
This webinar will begin by breaking down the biopsychosocial continuum and addressing the intersectional needs of our community. It will then move on to a panel discussion on living with uncertainty and the impact of trauma, ending with a discussion on the impact of living with congential malformations.
The outcome of the webinar will be the launch of a public call for expressions of interest to join the new EURORDIS Mental Wellbeing Partnership Network, where patient representatives will partner with experts to identify common mental health needs and inform EURORDIS’ strategic and policy action.
Podcast: Rare on Air
https://www.eurordis.org/rare-on-air/
Finding new uses for existing medicines
In our latest episode of Rare on Air, host Julien Poulain explores the potential of drug repurposing, which is the process by which new uses are discovered for already existing medicines. Julien is joined by Leonardo Panzeri, President of Italian Osteogenesis Imperfecta Association, and EURORDIS colleagues Claudia Fuchs and Judit Baijet, who all discuss the importance of patient advocates in drug repurposing efforts, as well as the EU-funded REMEDi4ALL project
BOOSTER TOWARD NEW SCIENTIFIC BREAKTROUGHS IN RARE AND PEDIATRIC DISEASES
https://www.rarediseasemoonshot.eu/
Rare Disease Moonshot, a coalition of seven organisations of which EURORDIS is a member, has issued recommendations to funders, researchers, patients, industry and other stakeholders on where public-private partnerships would bring most value in optimising clinical trials. The recommendations also include points to consider when setting up such collaborations that address the unmet needs of the rare disease community.
Welcome to the Best Practice Portal
https://webgate.ec.europa.eu/dyna/bp-portal/
Best practices in mental health
Upon acknowledging the distinct mental wellbeing needs of those with chronic illnesses, the European Commission has launched a call for best practices on mental health. The Commission is seeking examples of best and promising practices on mental health from governmental and non-governmental entities, which can be submitted via the EU Best Practice Portal by Friday 29 September.
Parkinson’s disease gene variant found in study of some people of African ancestry
Parkinson’s disease gene variant found in study of some people of African ancestry
NIH-supported, international study underscores importance of research of diverse populations.
https://www.nih.gov/news-events/news-releases/parkinson-s-disease-gene-variant-found-study-some-people-african-ancestry
miércoles, 23 de agosto de 2023
Researchers assemble the first complete sequence of a human Y chromosome
Researchers assemble the first complete sequence of a human Y chromosome
New sequence reveals genomic factors in fertility, including sperm production.
https://www.nih.gov/news-events/news-releases/researchers-assemble-first-complete-sequence-human-y-chromosome
MedWatch Online Voluntary Reporting Form: Correction: Hidden drug ingredients identified in products marketed for energy
https://www.accessdata.fda.gov/scripts/medwatch/index.cfm?utm_medium=email&utm_source=govdelivery
Health Fraud Product Database
https://www.fda.gov/consumers/health-fraud-scams/health-fraud-product-database?utm_medium=email&utm_source=govdelivery
BIG GUYS Male Energy Supplement contains hidden drug ingredient
https://www.fda.gov/drugs/medication-health-fraud/big-guys-male-energy-supplement-contains-hidden-drug-ingredient?utm_medium=email&utm_source=govdelivery
Mens Maximum Energy Supplement contains hidden drug ingredient
https://www.fda.gov/drugs/medication-health-fraud/mens-maximum-energy-supplement-contains-hidden-drug-ingredient?utm_medium=email&utm_source=govdelivery
Round 2 contains hidden drug ingredient
https://www.fda.gov/drugs/medication-health-fraud/round-2-contains-hidden-drug-ingredient?utm_medium=email&utm_source=govdelivery
Genergy contains hidden drug ingredient
https://www.fda.gov/drugs/medication-health-fraud/genergy-contains-hidden-drug-ingredient?utm_medium=email&utm_source=govdelivery
WeFun contains hidden drug ingredient
https://www.fda.gov/drugs/medication-health-fraud/wefun-contains-hidden-drug-ingredient?utm_medium=email&utm_source=govdelivery
X MAX Triple Shot Energy Honey contains hidden drug ingredient
https://www.fda.gov/drugs/medication-health-fraud/x-max-triple-shot-energy-honey-contains-hidden-drug-ingredient?utm_medium=email&utm_source=govdelivery
STARTUP AIMING TO KEEP KIDNEY PATIENTS OFF DIALYSIS
STARTUP AIMING TO KEEP KIDNEY PATIENTS OFF DIALYSIS
Electro-hydraulic acoustic therapy could treat late-stage chronic kidney disease and delay its progression by up to a year.
https://www.israel21c.org/startup-aiming-to-keep-kidney-patients-off-dialysis/
AI cancer startup collaborates with top Israeli hospital
AI cancer startup collaborates with top Israeli hospital
Cloud platform enables whole genome sequencing from data derived from blood tests that can detect recurring cancer early on.
https://www.israel21c.org/ai-cancer-startup-collaborates-with-top-israeli-hospital/
Drug Trials Snapshot: LUMAKRAS (SOTORASIB)
LUMAKRAS is a drug used to treat adult patients with non-small cell lung cancer (NSCLC) that is locally advanced or has spread to other parts of the body (metastatic). It should be used in patients who have been treated with at least one prior type of therapy and whose cancer has a certain type of genetic mutation (KRAS G12C).
https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-lumakras
martes, 22 de agosto de 2023
Bridget Williams-Simmons, Ph.D. Associate Director for Basic Research and Director of the Office of Science Policy and Communications, National Institute on Alcohol Abuse and Alcoholism
Bridget Williams-Simmons, Ph.D.
Associate Director for Basic Research and Director of the Office of Science Policy and Communications, National Institute on Alcohol Abuse and Alcoholism
https://www.spectrum.niaaa.nih.gov/spring2023fivequestions
Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021 Steinmetz et al.
Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00163-7/fulltext
Steinmetz et al.
https://www.thelancet.com/journals/lanrhe/home
Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study Fleischmann et al.
Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00161-3/fulltext
Fleischmann et al.
https://www.thelancet.com/journals/lanrhe/home
Public policy and health in the USA miniseries: should investors own healthcare?
Public policy and health in the USA miniseries: should investors own healthcare?
We are pleased to invite you to the latest event in our webinar miniseries public policy and health in the USA: should investors own healthcare?, Sept 26, 2023, at 14:00 EDT / 19:00 BST. Attendance is free and you can register for the webinar here.
Tues, Sept 26, 2023
13:00 EDT / 19:00 BST
https://event.on24.com/wcc/r/4261292/F83D33EB8BF67FD27D747E69F489D5E3?partnerref=hubspot_email_usinvestorshealthcare23_registration1&utm_campaign=usinvestorshealthcare23&utm_medium=email&_hsenc=p2ANqtz-9ocO9UuCNqvKDrzEYJ4NqsucxlkH4si8Pvdc_LiQ_tZ1BnsGCRL_Mk8lY_hDR8rnMhMhyPnzZl69BlgfJvEwRxLwXlYA&_hsmi=271132250&utm_content=270638876&utm_source=hs_email&hsCtaTracking=cf00ab02-c5b8-41eb-bf53-576b7acd0223%7Ce1788eb8-7603-46d7-8148-fb0020a6a949
FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants
FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants
https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants?utm_medium=email&utm_source=govdelivery
lunes, 21 de agosto de 2023
ZOOMED OUT: REBOOTING YOUR VIRTUAL ENGAGEMENT
Zoomed Out: Rebooting Your Virtual Communication
By Ivanhoe Broadcast News on August 27, 2023
https://www.ivanhoe.com/?p=31074&preview=1&_ppp=75cd9ee51b
OUTGROWING PENICILLIN ALLERGY?
Outgrowing Penicillin Allergy?
By Ivanhoe Broadcast News on August 25, 2023
https://www.ivanhoe.com/?p=31089&preview=1&_ppp=d1ee3adef4
TOO MUCH EXERCISE: CAN IT HURT YOUR HEART?
Too Much Exercise: Can it Hurt Your Heart?
By Ivanhoe Broadcast News on August 24, 2023
https://www.ivanhoe.com/?p=31092&preview=1&_ppp=c9d2407318
BORN WITH AVM: A SILENT KILLER OF YOUNG PEOPLE
Born with AVM: A Silent Killer of Young People
By Ivanhoe Broadcast News on August 23, 2023
https://www.ivanhoe.com/?p=31086&preview=1&_ppp=ff996ecdea
BATTLING OBESITY IN TEENS: GROUNDBREAKING GUIDELINES FOR CHILDREN
Battling Obesity in Teens: Groundbreaking Guidelines for Children
By Ivanhoe Broadcast News on August 22, 2023
https://www.ivanhoe.com/?p=31083&preview=1&_ppp=045cc5f9d2
CANCER & ORGAN TRANSPLANT CLINIC
Cancer & Organ Transplant Clinic
By Ivanhoe Broadcast News on August 21, 2023
https://www.ivanhoe.com/?p=31080&preview=1&_ppp=ee39ee1a79
Abdominal obesity and hydration status as protective factors against mortality in older adults: A prospective study Jarson Pedro da Costa Pereira, ... Poliana Coelho Cabral December 2023
Abdominal obesity and hydration status as protective factors against mortality in older adults: A prospective study
Jarson Pedro da Costa Pereira, ... Poliana Coelho Cabral
December 2023
https://www.sciencedirect.com/journal/nutrition
domingo, 20 de agosto de 2023
Pan American League of Associations for Rheumatology Guidelines for the treatment of ANCA-associated vasculitis
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00128-5/fulltext
"Gender bias is as entrenched as ever…with a shocking 9 out of 10 people globally reporting biases against women. It is imperative that we regain—and maintain—momentum in the drive to improve global gender equity."
https://www.thelancet.com/journals/lanrhe/home
sábado, 19 de agosto de 2023
Curious about your cancer risk, or if your child might develop learning disabilities? There’s a genetic test for that—but it may not be accurate E Prater, Fortune Well, July 2023
Curious about your cancer risk, or if your child might develop learning disabilities? There’s a genetic test for that—but it may not be accurate
E Prater, Fortune Well, July 2023
https://phgkb.cdc.gov/PHGKB/specificPHGKB.action?topic=cancer&query=home
Cluster of carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa among patients in an adult intensive care unit - Idaho, 2021-2022 Cahill ME , Jaworski M , Harcy V , Young E , Ham DC , Gable P , Carter KK .
Cluster of carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa among patients in an adult intensive care unit - Idaho, 2021-2022
Cahill ME , Jaworski M , Harcy V , Young E , Ham DC , Gable P , Carter KK .
https://phgkb.cdc.gov/PHGKB/cdcPubFinder.action?Mysubmit=update
The effect of personalized intelligent digital systems for self-care training on type II diabetes: a systematic review and meta-analysis of clinical trials. Mozhgan Tanhapour et al. Acta Diabetol 2023
The effect of personalized intelligent digital systems for self-care training on type II diabetes: a systematic review and meta-analysis of clinical trials.
Mozhgan Tanhapour et al. Acta Diabetol 2023
https://phgkb.cdc.gov/PHGKB/translationClip.action?action=nonGhome
What is Ocular Albinism?
Ocular albinism (OA) is an inherited genetic condition that primarily affects the pigments in the eyes.
https://www.news-medical.net/health/What-is-Ocular-Albinism.aspx
What is Akathisia?
Akathisia is a common movement disorder associated with the use of antipsychotic medications.
https://www.news-medical.net/health/What-is-Akathisia.aspx